Has Gilead (NASDAQ:GILD) moved so far from R&D and product development within its most core franchise, HIV/AIDS, that it has forgotten to protect those crown jewels quite as thoroughly as it might? Clearly, its HIV/AIDS franchise is strong and probably getting stronger. Yet ViiV is challenging it and in some ways, as shown below, it may be that GILD has ignored that challenge....More>>>
The U.S. dollar fell on Monday, losing ground against so-called commodity currencies as oil prices leapt on the prospects for an OPEC-led deal for continued production limits.
The greenback also lost ground against other major rivals, including the euro, extending the weakness the dollar saw on Friday, when downbeat economic data eroded much of last weeks gain.
The ICE U.S. Dollar....More>>>
Valeant Pharmaceuticals (NYSE:VRX) shares are on a tear, and the company’s first-quarter financial results show that management is making headway in paying down debt. However, the business itself continues to sputter, and ultimately this rally could be short-lived if sales can’t find their footing.
The good news
Valeanthas been struggling to offset declining sales following....More>>>
Over the past 12 months, Las Vegas Sands (NYSE:LVS) has risen by approximately 23%. As we enter 2017, investors must ask themselves whether these returns will continue or can they find better returns elsewhere. In my view, Las Vegas Sands’ shares are going to come under pressure in 2017, because dividend investors may begin to realize that the dividend does not have room to grow for reasons....More>>>
CVS Health (NYSE:CVS) reported its fourth-quarter financial results on Thursday. The big pharmacy services company beat its guidance, helped primarily by a strong performance from its pharmacy benefits management (PBM) segment. The bar had been lowered, however, because CVS reduced its fourth-quarter projections three months ago in light of contract losses to Walgreens Boot Alliance (NASDAQ:WBA).